Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03173404
Other study ID # 3913
Secondary ID
Status Completed
Phase N/A
First received May 30, 2017
Last updated May 30, 2017
Start date July 1, 2014
Est. completion date January 2017

Study information

Verified date May 2017
Source Instituto de Investigación Hospital Universitario La Paz
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a prospective randomized open-label trial. Women scheduled for their first or second in-vitro fertilization/intracytoplasmatic Sperm Injection (IVF/ICSI) cycle and with no abnormality detected in transvaginal ultrasound examination, were randomized to two groups. In the first group (group I) 31 patients underwent hysteroscopy examination before IVF cycle while in the second group (group II) 37 patients underwent direct cycle without previous hysteroscopy


Description:

This is a prospective randomized open-label trial. Women scheduled for their first or second IVF/ICSI cycle and with no abnormality detected in transvaginal ultrasound examination, were randomized to two groups. In the first group (group I) 31 patients underwent hysteroscopy examination before IVF cycle while in the second group (group II) 37 patients underwent direct cycle without previous hysteroscopy. Then IVF cycle was performed with habitual protocol. Beta Corionic Gonatropic hormone (BhCG) test two weeks after embryo transfer was done. If test was positive, patients were followed up for detection pregnancy by transvaginal ultrasound two weeks later. Another transvaginal ultrasound at 12 weeks of gestation was done to confirm ongoing pregnancy. Biochemical pregnancy, implantation, on-going pregnancy and livebirth rates were compared in both groups.

Miscarriage, complications rate and hysteroscopy tolerability were also analyzed.


Recruitment information / eligibility

Status Completed
Enrollment 75
Est. completion date January 2017
Est. primary completion date January 2017
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 40 Years
Eligibility Inclusion Criteria:

- Women with infertility / primary infertility.

- Women who are about to start an IVF/ICSI cycle with their own eggs.

- Age greater than or equal to 18 years and less than or equal to 40 years.

- Women in whom a multiple follicular development will be developed with a short protocol with antagonists or long with agonists, and starting dose of gonadotropins according to clinical criteria.

- Women with uterine ultrasound without endometrial pathology

Exclusion Criteria:

- Ovarian reserve: Antimullerian hormone <0.5 ng / dl or Count of antral follicles <5 between both ovaries.

- Myomatous uterus: presence of> 2 myomas> 4cm or that deform uterine cavity.

- Uterine malformations.

- Body mass index (BMI) <18 or> 30.

- Polycystic ovarian syndrome: according to European Society of Human Reproduction and Embryology (ESRHE)/Rotterdam 2003 criteria.

- Moderate-severe endometriosis.

- Background or presence of pelvic inflammatory disease.

- Hydrosalpinx not excised or occluded.

- Hyperprolactinemia, defined as prolactin levels greater than 50 ng / ml.

- Diagnostic history of endometrial hyperplasia.

- Severe male factor: severe oligoasthenoteratozoospermia with a sperm cell count (REM) <100,000 spermatozoa / ml.

- Impossibility to apply the treatments provided by the study in the terms established by the protocol.

- Contraindication for the use of any of the treatments provided in the study.

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Hysteroscopy
The hysteroscopy is the visualization of the cervical canal and uterine cavity with a camera. Patients randomized to group I underwent hysteroscopy prior to the IVF cycle.

Locations

Country Name City State
Spain La Paz University Hospital Madrid

Sponsors (1)

Lead Sponsor Collaborator
Instituto de Investigación Hospital Universitario La Paz

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of biochemical, clinical, on-going pregnancy and livebirth of IVF treatment Percentage of biochemical, clinical, on-going pregnancy and livebirth of IVF treatment comparing both groups. 12 months
Secondary Percentage of endocervical canal and uterine cavity pathology and the impact of treatment of these pathologies. Percentage of endocervical canal and uterine cavity pathology and the impact of treatment of these pathologies in the rate of pregnancy and livebirth. 12 months
Secondary Rate of hysteroscopy tolerance The tolerance of the procedure was evaluate in the patients randomized to the group I of the study. 1 month.
Secondary Hysteroscopy complication rate. We evaluate the complication of the hysteroscopy during and after the procedure. Includes blooding, infections, uterine perforation, etc. 2 months
See also
  Status Clinical Trial Phase
Completed NCT01955356 - Embryo Implantation After Induced Endometrial Injury N/A
Completed NCT01330771 - Assessment of the Therapeutic Utility of r-FSH in Association With hMG-HP N/A
Completed NCT01330784 - Assessment of the Therapeutic Utility of hMG-HP N/A
Active, not recruiting NCT05079685 - HyFoSy Versus HSG as a Diagnostic Technique for Tubal Patency.
Completed NCT04605003 - Effectiveness of Nasal Endoscope Sterilization Using a Novel Rig-S™ Device N/A
Completed NCT02607319 - Low Molecular Weight Heparin to Improve Pregnancy Outcome in Patients With Recurrent Implantation Failure Phase 4
Completed NCT01331720 - Assessment of the Effectiveness and Tolerability of Ovarian Hyperstimulation N/A
Completed NCT01331733 - Comparative Assessment of the Clinical Utility of Ovarian Stimulation With Menotropin Versus Menotropin Plus GnRH Antagonist N/A
Not yet recruiting NCT02648555 - A Lifestyle Intervention to Improve in Vitro Fertilization Results N/A
Suspended NCT00749853 - Efficacy of Ovarian Stimulation Based on FSHR Genotype Status Phase 3
Recruiting NCT03177122 - Myo-Inositol- Based Co-treatment in Women With PCOS Undergoing Assisted Reproductive Technology Phase 4
Completed NCT03169166 - The Use of GnRH Agonist Trigger for Final Follicle Maturation in Women Undergoing Assisted Reproductive Technologies Phase 4
Completed NCT01406964 - Chlamidia Antibodies Test for Tubal Factor Screening N/A
Completed NCT01430650 - Endometrial Priming for Embryo Transfer Phase 4
Completed NCT03561129 - Embryotransfer Operator and Pregnancy Rate
Recruiting NCT05173597 - Real-world Evidence on Follitropin Delta Individual Dosing
Recruiting NCT04026282 - To Investigate the Cumulative Live Birth Rates Using GnRH Antagonist or Agonist Protocol for COS in ART Treatment N/A
Completed NCT03619707 - Oral Versus Vaginal Progesterone in the Luteal Support in Cryo-warmed Embryo Transfer Cycles Phase 4